Bromfenac is a nonsteroidal anti-inflammatory drug indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. It is available as eye drops and ophthalmic solution. MedsAcross supplies Bromfenac for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Bromfenac Ophthalmic Solution 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac Ophthalmic Solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Source: US FDA prescribing information
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
Source: US FDA prescribing information
Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days postsurgery.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Sulfite Allergic Reactions. Slow or Delayed Healing. Potential for Cross-Sensitivity. Increased Bleeding Time. Keratitis and Corneal Reactions
Source: US FDA prescribing information
The most commonly reported adverse reactions in 3% to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision.
Source: US FDA prescribing information
Storage Store at 15ºC to 25ºC (59ºF to 77ºF).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
9 presentations of Bromfenac, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Bromfenac 0.7 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Bromfenac 0.9 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Bromfenac 0.805 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Bromfenac 1.035 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Prolensa 0.7 mg/mL eye dropsOphthalmic | Bausch & Lomb | US FDA | Available on request |
| Bromfenac 0.75 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Bromfenac 0.76 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Bromfenac 0.9 mg/mL ophthalmic solutionOphthalmicGeneric name | — | US FDA | Available on request |
| Bromsite 0.075% 0.76 mg/mL eye dropsOphthalmic | Sun Pharmaceutical IndustriesIndia | US FDA | Available on request |
2 brand names across 1 markets.
United States
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Bromfenac in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 9 presentations of Bromfenac and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Sun Pharmaceutical Industries.
The catalogue lists 2 brand names for Bromfenac, including Bromsite 0.075%, Prolensa.
Yes. The US FDA first approved Bromfenac on 24 March 2005, according to Drugs@FDA.
Yes. Bromfenac has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Bromfenac is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Bromfenac is classified under ATC code S01BC11 (Bromfenac).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.